Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. by Blakey, D. C. et al.
R J(19in-- d Cacer (1395)72 1083-1088
© 1995StocDn Press Al rhts resved 0007-0920/95$12.00
Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in
combination with phenol mustard prodrugs
DC Blakey', DH Davies', RI Dowell', SJ East', PJ Burke', SK Sharma2, CJ Springer3,
AB Mauger3 and RG Melton4
'Cancer Research Department, Zeneca Phannaceuticals, Alderley Park, Macclesfield, Cheshire SKJO 4TG, UK; 2Department of
Medical Oncology, CRC Laboratories, Charing Cross Hospital, London W6 8RF, UK; 3CRC Centrefor Cancer Therapeutics
Institute ofCancer Research, Sutton, Surrey SM2 5NG, UK; 4PHLS Centrefor Applied Microbiology and Research, Division of
Biotechnology, Porton Down, Salisbury, Wilts SP4 OJG, UK.
S_ary ADEPT is an antibody-based targeting strategy for the treatment of cancer. We have developed
two new prodrugs, 4-N,N-bis(2-chloroethyl)amino-phenoxycarbonyl-L-glutamic acid (PGP) and (S)-24N-N4-
[N,N-bis(2-chloroethyl)amino]phenoxycarbonyllaminol-4-(5-tetrazoyl)butyric acid (PTP), which are cleaved by
the bacterial enzyme CPG2 to release the 4-N,N-bis(2-chloroethyl)aminoJ phenol drug. In vitro, both prodrugs
are approximately 100- to 200-fold less potent than the parent drug (1 h IC50 = 1.41M) in LoVo colorectal
tumour cells. These prodrugs have been evaluated for utility in ADEPT when used in combination with a
conjugate of CPG2 and the F(ab32 fragment of the anti-CEA monoclonal antibody, A5B7. The conjugate was
shown to localise specifically to established LoVo tumour xenografts growing in nude mice and optimal
tumour-normal tissue ratios were achieved after 72 h. Administration of either prodrug, at doses which cause
6-8% body weight loss, 72 h after administration of the A5B7-CPG2 conjugate to the LoVo tumour-bearing
mice resulted in tumour regressions and growth delays of 14-28 days. The ml? prodrug in combination with
a high dose of conjugate (10mglkg-') gave the best anti-tumour activity despite being a 10-fold worse
substrate for CPG2 than PGP. Prodrug alone, active drug alone or prodrug in combination with a non-specific
conjugate had minimal anti-tumour activity in this tumour model.
Keywords: antibody-directed enzyme prodrug therapy; antibody; prodrugs; antibody-enzyme conjugate; anti-
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Antibody-directed enzyme prodrug therapy (ADEPT) has
been developed as an antibody-based targeting strategy for
the treatment of cancer (Bagshawe, 1987; Bagshawe et al.,
1988; Senter et al., 1988; Deonarain and Epenetos, 1994).
The first step involves the administration of a tumour-
selective antibody linked to an enzyme. Following tumour
loclisation of the conjugate and clearance of conjugate from
blood and normal tissues, the second step involves administ-
ration of an inactive prodrug which is converted by the
targeted enzyme at the tumour site into a potent cytotoxic
drug. ADEPT has a number of potential advantages over
other forms of antibody-based targeted therapy. Each
enzyme molecule can potentially convert a large number of
prodrug molecules into drug molecules at the tumour site.
Potency limitations of directly targeting a cytotoxic drug
molecule to a tumour with an antibody caused by the fact
that only a limited number of drug molecules can be directly
attached to an antibody without compromising tumour
targeting (Thorpe, 1985) are thus overcome by ADEPT. A
second advantage is that a small molecular weight cytotoxic
drug is generated locally at the tumour site and outside the
cell. The drug should be capable ofdiffiusion to reach tumour
cells not directly targeted by the conjugate either owing to
antigenic heterogeneity (Woodruff, 1983) or because the high
molecular weight conjugate has failed to diffuse away from
the tumour vasculature and reach tumour cells distant from
the blood supply (Jain, 1989).
We have previously reported on an ADEPT system which
utilises the bacterial enzyme carboxypeptidase G2 (CPG2)
(Bagshawe et al., 1988; Springer et al., 1991a). CPG2 has no
known mammalian equivalent and catalyses the hydrolytic
cleavage of reduced and non-reduced folates to pteroates and
L-glutamate (Minton et al., 1983). The amide bond in the
glutamate derivatives of benzoic acid mustards are also
cleaved by CPG2 to release the benzoic acid mustard drug. A
series of studies has shown that the combination of these
benzoic acid mustard-glutamate prodrugs and a conjugate
of CPG2 linked to either the anti-$-hCG antibody, W14
(Bagshawe et al., 1988; Springer et al., 1991a) or the anti-
CEA antibody, A5B7 (Blakey et al., 1993) results in
signficant anti-tumour activity in a number of tumour
models. Clinical trials are ongoing with the 44(2-
chloroethyl)2-mesyloxyethyl)amino]-benzoyl-L-glutamic acid
prodrug (CMDA) and an F(ab%A5B7-CPG2 conjugate in
patients with advanced colorectal cancer (Bagshawe et al.,
1991; Bagshawe, 1993).
Two potential limitations of these ADEPT systems incor-
porating benzoic acid mustard prodrug are firstly that the
drugs generated are not very potent (Springer et al., 1991b;
Blakey et al., 1993) and secondly that the drugs have
relatively long chemical (60 min) (Springer et al., 199lb) and
biological (1.6 h) half-lives (Antoniw et al., 1990) which
potentially permit escape of the drug from the tumour site
into the periphery resulting in enhanced non-specific toxicity.
In this paper we describe the evaluation of two new pro-
drugs which are cleaved by CPG2 to release a potent and
highly reactive phenol mustard drug. When compared with
the original benzoic acid mustard prodrugs described
previously (Bagshawe et al., 1988, Springer et al., 1991a;
Blakey et al., 1993) these prodrugs when used in combination
with the F(ab%A5B7-CPG2 conjugate result in improved
anti-tumour activity in a colorectal tumour xenograft model.
Matedak and methods
The prodrugs used in these studies are 4-tN,N-bis(2-chloro-
ethyl)aminoJ-phenoxycarbonyl-L-glutamic acid (phenol glut-
amate prodrug; PGP) and (S)-2{NN4-[N,N-bis(2-chloro-
ethyl)amino]-phenoxycarbonylJamino]-4-(5-tetrazoyl)butyric
acid (phenol tetrazole prodrug; PTP). The structure of these
prodrugs and the corresponding phenol drug are shown in
Figure 1. Their synthesis will be described elsewhere (RI
Dowell et al., unpublished data; DH Davies et al., unpub-
lished data).
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Figwe 1 Structure of PGP, PTP and phenol mustard drug.
Methotrexate was obtained from Sigma, Poole, Dorset.
Carboxypeptidase G2 from Pseudomonas sp strain RS16
was cloned into Escherichia coli (Minton et al., 1983) and
prodneed as described by Sherwood et al. (1985). A5B7
antibody (IgGI) which reacts with the carcinoembryonic
antigen (CEA) was kindly supplied by the Department of
Medical Oncology, CRC Laboratones, Charing Cross Hos-
pital (Harwood et al., 1986). MOPC-21 (IgGl) control
antibody which has no known tissue reactivity was generated
from the hybridoma cell line P3X63Ag8 acquired from the
European Collection of Animal Cell Cultures (ECACC no.
85011401). The F(ab% fragment of A5B7 and MOPC were
prepared by papain digestion. For A5B7 and MOPC
enzyme-antibody ratios of 1:70 for 24 h at 3TC and 1:20 for
4h at 3TC were used respectively. The F(ab% fragments
were conjugated to CPG2 as described previously by Melton
et al. (1993). Both conjugates had sp. act. of 150-200 U
CPG2mg'I protein and predominantly consisted of one
F(ab% fragment ofA5B7 conjugated to one CPG2 molecule.
The molkular weight of these conjugates is thus approx-
imately 180 kDa. One unit of CPG2 activity corresponds to
the amount of enzyme required to hydrolyse 1 pmnol of
methotrexate min' ml- 'reacion mixture at 3TC (Sherwood
et al., 1985).
The LoVo colorectal tumour cell ne was obtained from
the European Collection of Animal Cell Cultures (ECACC
no. 87060101).
E;nzyme kinetics
The K. and k,. of the prodrugs for CPG2 was determined
using a method based on the literature CPG2 assay method
for methotrexate (Sherwood et al., 1985). The absorbances of
prodrug and corresponding drug were scnned from 200 nm
to 350 nm using a spectrophotometer (Perkin Elmer Lambda
2) and the wavelength where the maximal absorbance
difference (due to cleavage ofthe carbamate linkage) tween
prodrug and drug was determined. For PGP and PTP this
was 258 and 259nm respectively and theA2m, for PGP=
16.1 x103M-'cm- and theAs2m for PTP= 15.3 x 103m-1
cm-'. The Km and V.. were determined by measuring the
initial rate of conversion of prodrug to drug at these
wavelengths using a range of prodrug concentrations
(1-100IM) and CPG2 enzyme concentrations (0.05-1 U).
The k,, was calculated from the V.= by dividing by the
amount of CPG2 in the reaction mixture.
Cytotoxicity Studies
The colorectal tumour cell line LoVo (CEA positive and
A5B7 reactive) was incubated with prodrug, prodrug phls
CPG2 (1.0 U per well) or drug, in 96-well (2500 cells per
well) microtitre plates for 1 h. The cells were then washed
and incubated for a further 3 days at 3TC. Trichloroacetic
acid (TCA) was then added and the amount of cellular
protein adhering to the plates was assessed by the addition of
SRB dye according to Skehan et al. (1990). Potency of the
compounds is expressed as the concentration required to
inhibit cell growth by 50% (IC,4).
Tumour localisation studies
The F(ab%A5B7-CPG2 conjugate was radioiodinated with
carrier-fiee iodine-125 using the lodogen reagent, following
the manufacturer's rm ed method. In vitro retention
of >70% immunoreactivity after radioiodination was
confirmed by binding to LoVo cells using the method of
Lindmo et al. (1984). Approximately 101g ofconjugate con-
taining 10pCi'I was injected i.v. into athymic nude mice
[nu/nu:Alpk(outbred)] bearing established LoVo tumour
xenografts (1 x I07 LoVo tumour cells injected s.c. 7 days
previously). Following injection of the conjugate, groups of
three mice were killed 4, 24, 72 and 168 h later. The tumour,
a sample ofblood and a range ofother tissues were removed,
weighed and counted in a gamma counter.
Toxicity studies
Groups of five female Alderley Park mice were injected with
prodrug (three doses at 1 h intervals) i.p. 3 days after injec-
tion of F(ab%A5B7-CPG2 conjugate (500 or 200 U
CPG2kg-' i.v.) Body weight and condition of the mice was
monitored daily. A dose of prodrug was established which
caused 15% body weight loss (defined as the MTD in thesePhe musvd -
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studies) on at least 1 day after treatment. Body weight loss
was generally maximal at days 2-3 and mice generally
regained body weight by day 7 after treatment with prodrug.
Preliminary studies were carried out with groups of two
mice to establish the approximate MTD thus minimising the
number of animals required to obtain an accurate MTD. The
toxicity of conjugate and either PGP or PTP prodrug in
normal and tumour-bearing athymic nude mice were not
significantly different.
Anti-twnour studies
Groups of 8-10 female athymic nude mice were injected s.c.
with 1 x 10' LoVo tumour cells. When the tumours were
4-5 mm in diameter F(ab')2A5B7-CPG2 conjugate (500-
2000 U CPG2 enzyme activity Kg-') or phosphate-buffered
saline (PBS), was injected i.v. Seventy-two hours later pro-
drug was injected i.p. (three doses at 1 h intervals). The
length of the tumours in two directions was then measured
three times a week and the tumour volume calculated using
the formula:
Volume = it 6 x DY x d
where D is the larger diameter and d is the smaller diameter
of the tumour.
Tumour volume was expressed relative to the tumour
volume at the time of initiation of the prodrug arm of the
therapy. At this stage tumours measured 7-8 mm in
diameter and had a calculated weight (assuming a density of
1.0) of approximately 0.2-0.3 g. The anti-tumour activity
was compared with control groups given PBS instead of
either conjugate or prodrug. Other groups of tumour-bearing
mice received F(ab')2MOPC-CPG2 control conjugate fol-
lowed by prodrug or they were given prodrug or phenol
mustard drug alone at the same time as the prodrug was
administered in the combination arm of the study. Toxicity
was monitored throughout the studies by measuring body
weight and monitoring the condition of the animals. Statis-
tical significance of the anti-tumour effects was judged using
the analysis of variance (one-way) test (Armitage and Berry.
1987).
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Figure 2 In vitro cytotoxicity of PGP. PTP and phenol mustard
drug im LoVo colorectal tumour cells. LoVo cells were incubated
for I h with (a) phenol mustard drug (0) or PGP either alone
(O) or with 1U CPG2 (U) or (b) with phenol mustard drug (0)
or PTP either alone (O) or with 1U CPG2 (-). Cytotoxicity was
assessed using the SRB dye assay after a further 3 days. Each
point represents the mean of triphcate determinations.
Results
In vitro properties ofprodrugs
The PGP and PTP prodrugs both contain a carbamate lin-
kage between the phenol mustard drug and either a glutamic
acid moiety in the case of PGP or an analogue of glutamic
acid containing a tetrazole unit in the case of PTP. They
were both good substrates for CPG2 and were cleaved to
release the phenol mustard drug. The K. and k, for PGP
and PTP are shown in Table I. PGP has a low K, which is 5-
to 10-fold lower than either PTP or methotrexate (the stan-
dard substrate for CPG2). Consequently, although both PGP
and PTP have similar kr values for CPG2, the turnover
number (k/.K^,) for PGP is approximately 10-fold higher
than for PTP. This demonstrates that PGP is more efficiently
converted to drug by CPG2 than is PTP.
The cytotoxicity of PGP and PTP in vitro in LoVo colorec-
tal tumour cells and the corresponding phenol mustard drug
released following cleavage by CPG2 are shown in Figure 2a
and b. PGP and PTP had IC50 values of 254 and 175lM
respectively (mean value of at least six separate studies) after
Table I Enzyme kinetic properties of the prodrugs against CPG2
Compound K. (gM) kc (s '}) kc/K. (s FtM '
Methotrexate 9.5 510 54
PGP 1.0 (0.5) 49 (25) 49
PTP 12.4 (4.6) 67 (11) 5.4
K,,, andk. values for PGP and PTP represent mean values ofat least
three separate determinations with standard deviations in parentheses.
Methotrexate values are mean data of two separate determinations.
a 1 h incubation with LoVo colorectal tumour cells. Both
prodrugs were some 100- to 200-fold less cytotoxic than the
corresponding phenol mustard drug (IC50 = 1.4pM). Addi-
tion of I U of CPG2 to either PGP or PTP for 1 h in vitro
resulted in an equivalent cytotoxicity in LoVo cells to the
active drug (Figure 2a and b) thus confirming the ability of
CPG2 to catalyse the release of active drug from either
prodrug.
Localisation ofF(ab')2A5B7-CPG2 to LoVo tumour
xenografts
The ability of the F(ab')2A5B7-CPG2 conjugate to localise
to LoVo tumour xenografts in nude mice was evaluated by
radioiodinating the conjugate and measuring the tumour,
blood and normal tissue levels after injection into nude mice
bearing established (approximately 0.2-0.4 g) LoVo tumour
xenografts. LoVo tumour cells express CEA and in vivo, as
judged by immunohistology, approximately 60% of the
LoVo cells react with A5B7 in the tumour xenografts (results
not shown). The ability of the conjugate to localise to these
LoVo tumour xenografts is shown in Figure 3. After 24 h
approximately 2.5% of the injected dose of conjugate was
present per g of tumour but at this time point there was
more conjugate (3.2%) present in the blood. After 72 h app-
roximately 1% of the injected dose was present per g of
tumour and this level now exceeded the amount present in
blood and normal tissues by a factor of 3 and 10- to 50-fold
respectively. Levels of conjugate in all normal tissues
examined (liver, kidney, stomach, lung, skin) were less than
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prodrug following administration of either conjugate dose.
Blood enzyme levels were determined 72 h following adminis-
tration of either 500 or 2000 U kg-' conjugate and were
found to be 0.05 and 0.2 Uml-' plasma respectively.
The anti-tumour effects of the PGP and PIP prodrugs in
LoVo tumour xenografts are shown in Figure 4a and b and
summansed in Table III. Both the 500 U and 2000 U kg-'
conjugate dose levels were evaluated in combination with a
prodrug dose which represented half the MTD (Table HI) and
caused 7-8% body weight loss. Both prodrugs caused regres-
sion of the tumours and significant (P<0.05) growth delays
24 72
Time (h)
168
Figue 3 Localisation of F(ab'),A5B7-CPG2 conjugate to LoVo
tumour xenografts. Athymic nude mice bearing established LoVo
tumours were injected with radioiodinated F(ab')A5B7-CPG2
conjugate. At various time intervals blood ( [ ), liver ( _ ) or
tumour ( M ) were removed and the radioactivity they contained
was measured in a gamma counter. Results were expressed as %
of the injected dose g-' tissue and represent the mean values
from three mice at each time point.
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0.1% injected dose g-' at this 72 h time point. By 7 days
only small amounts of conjugate remained in the tumour,
blood and normal tissues. The level of conjugate and the
tumour-blood ratio at 72 h did not vary over a conjugate
dose range of 100-2000 U kg-' F(ab')A5B7-CPG2 con-
jugate (results not shown). Based on these data a time inter-
val of 72 h between conjugate and prodrug administration
was chosen for the anti-tumour studies.
Anti-tmnour activity
A prodrug dosing regimen of three doses hourly over a 2 h
time period was selected since both the PGP and PTP pro-
drugs have relatively short biological half-lives in mice of
20-30 min (results not shown) and it was thought that this
dosing regimen might optimise exposure of prodrug to
enzyme at the tumour site. Two conjugate dose levels were
evaluated (500 and 2000 U CPG2 kg-1 corresponding to app-
roximately 2.5 and 10 mg kg-' of total protein). The dose of
prodrug, in combination with these conjugate dose levels,
that caused 15% body weight loss was established, and the
results are shown in Table II. Based on body weight loss, the
PGP prodrug was 7- to 8-fold more toxic than the PTP
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Table k Toxicity of PTP and PGP prodrugs
Conjugate dose Prodrug dosea (mgkg-')
(ULCPG2kg-1) PTP PGP
500 3 x 50 3 x 350
2000 3 x 24 3 x 204
'Prodrug dose which in combination with conjugate level results in
15% body weight loss in mice. This dose is defined as the maximum
tolerated dose (MTD).
Fugwe 4 Anti-tumour activity in LoVo tumours of PGP and
PTP in combination with F(ab%A5B7-CPG2 conjugate. LoVo
tumour growth curves (mean values for 8-10 mice per group) for
mice receiving (a) PBS (O), PGP prodrug (3 x 25 mg kg ') alone
(-), phenol mustard drug (3 x 2mg kg-') alone (0) or PGP
prodrug (3 x 25mgkg-') 3 days after either F(ab%kMOPC
CPG2 (0) or 500CPG2U kg-' F(ab%)A5B7-CPG2 (0) or (b)
PBS (0), PTP prodrug (3 x 175 mg kg-') alone (U), phenol
mustard drug (3 x 2 mg kg-') alone (0) or PTP prodrug
(3 x 102 mg kg-') 3 days after either F(ab})MOPC-CPG2 (0)
or 2000U CPG2 kg-' F(ab')A5B7-CPG2 (0).
Table m Anti-tumour activity of PGP and PTP in LoVo tumour xenografts
PGP PTP
Conjugate dose Dose TIC" Growth delaqy Dose TIC Growth delay
(UCPG2kg-') (mgkg-}) (%) (days) (mgkg1 (%J (days)
ff 3x25 62 2 3x175 64 1
500" 3x25 14(2) 16(5) 3x 175 18(4) 19(4)
2000C 3 x 12 34 15 3 x 102 7 28
'T/C, the volume ofthe treatedtumour/volume ofthe control tumour 14days afterprodrug administration.
bGrowth delay is the time it takes treated tumours to increase their volume by 4-fold minus the time it takes
control tumours to increase their tumour volume 4-fold. cData are mean values oftwo separate studies. 'Data
are mean values of three separate studies with standard deviations in parentheses.
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of 14-28 days compared with control tumours. The most
effective regumen was the FTP prodrug combination with
the 200 U kg-' conjugate dose. FP prodrug was
significantly (P<0.05) more active in combination with the
2000 U kg-I conjugate dose than with the 500 U kg- con-
jugate dose. The activity of PGP with either conjugate dose
was not significntly different.
If PGP or PTP were adminisred in the absence of con-
jugate or the active phenol mustard drug was administered
(3 x2mg kg-') at a dose which caused 7-8% body weight
loss, growth delays of less than 5 days were seen (Figure 4).
Similarly, if the F(ab%A5B7-CPG2 conjugate was replaed
with a control F(ab)2MOPC-CPG2 conjugate which does
not bind to LoVo cells, growth delays with either PGP or
PTP were seen of leIs than 5 days (Figure 4). The plasma
enzyme levels of the F(ab%MOPC-CPG2 conjugate were
the same as those with the specific F(ab)A5B7-CPG2 con-
jugate at the time of prodrug administration (72 h) in these
therapy studies. Thus to achieve tumour regrssions and
growth delays>5 days, the combination of both the specific
conjugate and prodrug was required.
The major finding to emerge from these studies is that we
have been able to develop two new prodrugs of a potent
phenol mustar drug which in combination with an
F(ab%A5B7-CPG2 conjugate result in pronounced anti-
tumour activity in a colorectal tumour xenograft model. The
enzyme used in this ADEPT system, CPG2, is a bacterial
carboxypptidasewith specificity for cleavage of amie bonds
with a C-terminal
glutamic acid residue. Previously it has
been demonstrated that CPG2 is capable of cleaving amide
bonds in both methotrexate (Sherwood
et al., 1985) and
benzoic acid musard-glutamate prodrugs(Bagshawe
et al.,
1988; Springer
et al., 1991a). Surprisingly, both PGP and
PIP are very good substrates for CPG2 despite the fact that
they contain a carbamatelinkage (Table I).
The phenol mustard drug liberated from PGP andFTP by
CPG2 is some 50- to 100-fold more potent than the benzoic
acid mustard drug liberated from the CMDA prodrug (Spr-
inger
et al., 1991b; Blakey et al., 1993) which is currently in
chnical
trials combination with the F(ab%A5B7-CPG2
conjugate (Bagshawe et al., 1991, 1995; Bagshawe, 1993). The
increase potency along with retention of good enzyme
kinetics should mean less conjugate is required at the tumour
site for the conversion of sufficient prodrug to drug to result
in anti-tumour activity. In addition, the drug generated has a
very short chemical half-life of approximately 5 min in buffer
at 3TC (RJ Dowell et at., unpublished data) when compared
with drug generated from CMDA which has a half-life of
approximately 60 min (Springer
et al., 1991b). This reduction
in half-life should have the advantage that drug generated
within the tumour will be
less able to escape into the
periphery and cause toxicity.
Attachment of either the acid or tetrazole
glutamic acid residue via the arbamate link to the phenol
mustard reduces it cytotoxic potency by greater than 100-fold
(Figure 2). Sine the chemical rctivity and thus
intrinsic
alkylating activity of the mustard arms is only reduced by
approximately 6-fold in both PGP andPTP (RI Dowell
et
al., unpublished data; DH Davies
et al., unpublshed data) it
seemslikely that the major reason for thedrease in
cytotoxicity is that the anionic groups in the glutamate and
tetrazole residues decrease the rate of uptake of the prodrug
by the cells. However, we have no direct data to confirm this
hypothesis.
The localisation of the F(ab%A5B7-CPG2 conjugate to
LoVo tumour xenografts (Figure 3) is similar to that
reported previously in LS174T colorectal tumours (Blakey
et
al., 1993). The opfimal time for prodrug administration is a
balance between reaining sufficient conjugate at the tumour
site to activate sufficient drug for tumour cell ki vs ensuring
that the level of enzyme in the blood and normal issues does
not cause excessive toxicity. We have been able to define a
time interval when this criteria is met as judged by the
anti-tumour results. In other instan, including the com-
bination of CMDA prodrug and F(ab%A5B7-CPG2 con-
jugate, the use of a claring system has been used to improve
anti-tumour activity (Sharma et al., 1990, 1991). The claring
systms accelerate the blood cleance of the conjugate,
enabling prodrug to be administered when tumour enyme
levels are higher. The major disadvantage of using a clearing
system is that it adds an additional level of complexity to the
ADEPT approach.
Significantly more PTP than PGP prodrug could be
administered to mice 72 h after conjugate administration.
Since both prodrugs release the same active drug, have
similar cytotoxicties in vitro (Figure 2) and have similar
pharmacokinetics in mice (unpublished data) it seems likely
that this is due to the fact that PTP is approximately a
10-foldkss effective substrate for CPG2 thanPGP as judged
by the turnover number (k,,,/K.). Residual enzyme levels in
the blood and normal tiss is likely to convert less PTP
prodrug to drug than is the case with thePGP prodrug and
consequently more FTP prodrug can be ani . While
PGP produces similr anti-tumour activity at both the 500
and 2000 U kg- conjugate dose, the anti-tumour activity of
PTP wassigniiantly better with the 2000 compared with the
500 U kg-' conjugate dose in two separate stuies. These
data support the suggeston, based on computer modelling,
that for optimal seectivity a prodrug with relatively poor
enzyme kinetics may be more favourable for ADEPT (Yuan
et al., 1991). The rationale for this is that such a prodrug
would optimise the usage of conjugate localsed at the
tumour site. A prodrug which is a very good substrate for
the enzyme may be rlipidly tuned over in the periphery by
even small quantities of residual enzyme, thus reducing prod-
rug levels that can reach the tumour to be converted by
targeted enzyme.
In the absence of a cearing system the original CMDA
prodrug in combination with F(ab%A5B7-CPG2 in either
LoVo (unpubished data) or LS174T colorectal tumour
xenografts (Blakey et al., 1993) only gives 8- to 10-day
growth delays andlittle evidence of tumourregreison at
doses of prodrug which cause similar toxicity to those seen in
the therapy studies reported here. Thus by increasing the
potency and reactivity of the drug released and altering the
enzyme kinetics of the prodrug for CPG2 we have been able
to improve the original CMDA prodrug in terms of anti-
tumour actity in colorectal xenografts using a two-step
ADEPT approach.
Previously, Wallace and Senter (1991) reported an ADEPT
system which incorporated a different prodrug of the phenol
mustard drug used in these studies. The prodrug wasp[NVN-
Bis(2chothyl)aminonyl phosphate (POMP) and the
enzyme used to cleave the phosphate residue to release the
drug was alkaline phosphatase. In a lung tumour xenograft
model (H2981) the combination of antibody-alkalne phos-
phatase conjugate and POMP rulted 10- to 15-day
growth delays with little evidence of tumour regressions. The
activity of this system was probablylimited by endogenous
alkaline phosphatase causing conversion of prodrug to drug
and so enhancing toxicity. Since CPG2 is a bacterial enzyme
and no active drug has been detected following the administ-
ration of the CMDA prodrug to patients in the absence of
conjugate (Bagshawe, 1993; Bagshawe et al., 1995) the
presence of endogenous enzyme is unlikely to be a problem
with the ADEPT system described in thesestudies. No
phenol mustard drug was detected after administration of
eitherFTP orPGP to mice in the absence of conjugate
(unpublished data).
The anti-tumour effects ofPNP and TPin combination
with F(ab%2A5B7-CPG2 were dependent on targeting of the
conjugate to the tumour. A control conjugate prepared with
the MOPC antibody which does not bind to LoVo tumour
cells when used in combination withPGP orPTP resulted in
little anti-tumour activty. This was despite the fact that the
plasma enzymeevels of the two conjugates were the same at
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72 h. Similarly. prodrug alone or the phenol mustard drug
resulted in little anti-tumour activity.
In conclusion, we have developed a new ADEPT system
which incorporates prodrugs of phenol mustard drug and the
conjugate F(ab')2A5B7-CPG2. This ADEPT system results
in tumour regression and significant tumour growth delays in
a colorectal tumour xenograft model demonstrating its
potential for treatment of colorectal cancer.
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